



Simoa® Technology Powering Advancements in Neurology

Quanterix empowers researchers with cutting-edge Simoa® digital immunoassays that measure both established and emerging biomarkers in neurology. Simoa® technology sets the gold standard for early biomarker detection in serum, plasma, or CSF, quantifying proteins at levels far below the conventional ELISA Level of Quantification (LoQ). Rely on our industry-leading precision instruments, Simoa® digital immunoassay technology, and CLIA-certified Accelerator laboratory to support research that advances our understanding and management of neurological disorders.

	NfL	GFAP	T-Tau	BD-Tau	p-Tau 181	p-Tau 217	p-Tau 231	SNAP-25	TDP-43	BDNF	Inflammatory cytokines*	Neuro 2-Plex B (NfL, GFAP)	Neuro 3-Plex A (T-Tau, Aβ42, Aβ40)	Neuro 4-Plex A/B (NfL, T-Tau, BD-Tau, UCH-L1)	Neuro 4-Plex D (NfL, BD-Tau, GFAP, UCH-L1)	Neuro 4-Plex E (Aβ42, Aβ40, GFAP, NfL)
Alzheimer's Disease	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓
Multiple Sclerosis	✓	✓									✓	✓				
Traumatic Brain Injury	✓	✓	✓	✓	✓		✓			✓	✓	✓		✓	✓	✓
Amyotrophic Lateral Sclerosis	✓	✓							✓	✓	✓	✓				
Frontotemporal Dementia	✓	✓							✓	✓	✓	✓				
Stroke	✓	✓	✓	✓								✓		✓	✓	
Parkinson's Disease	✓		✓		✓		✓				✓					
Epilepsy	✓		✓		✓		✓				✓					
Major Depressive Disorder	✓									✓	✓					
Spinocerebellar Ataxia	✓	✓	✓									✓		✓		
Brain Hypoxia	✓	✓	✓									✓	✓	✓		
Huntington's Disease	✓															
Neurotoxicity	✓	✓										✓				
Infectious disease associated neuronal injury	✓	✓										✓				
Prion diseases	✓		✓	✓	✓	✓	✓							✓		
Spinal Muscular Atrophy	✓															

*Quanterix is expanding our assay menu to include multiplex cytokine panels that measure both pro-inflammatory and anti-inflammatory cytokines. These panels will be ideal for studying neuro-inflammatory conditions in combination with our neurology assays.